A muscarinic receptor agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cevimeline (hydrochloride)

Item No. 17802

Technical Information
Formal Name
(2’R,3R)-rel-2’-methyl-spiro[1-azabicyclo[2.2.2]octane-3,5’-[1,3]oxathiolane], monohydrochloride
CAS Number
107220-28-0
Synonyms
  • AF 102B
  • SNI 2011
  • SNK 508
Molecular Formula
C10H17NOS • HCl
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 3 mg/mlDMSO: 5 mg/mlEthanol: 5 mg/mlPBS (pH 7.2): 10 mg/ml
SMILES
C[C@@H](SC1)O[C@@]21CN3CCC2CC3.Cl
InChi Code
InChI=1S/C10H17NOS.ClH/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;/h8-9H,2-7H2,1H3;1H/t8-,10-;/m1./s1
InChi Key
SURWTGAXEIEOGY-GHXDPTCOSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Cevimeline is a muscarinic receptor agonist (EC50s = 23, 48, and 63 nM for M1, M3, and M5, respectively, and >1 µM for M2 and M4).1 It stimulates secretion by salivary glands and is useful in ameliorating xerostomia (dry mouth).2,3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Heinrich, J.N., Butera, J.A., Carrick, T., et alPharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists. Eur. J. Pharmacol. 605(1-3), 53-56 (2009).

    2. Kahn, S.T., and Johnstone, P.A. Management of xerostomia related to radiotherapy for head and neck cancer. Oncology (Williston Park) 19(14), 1827-1832 (2005).

    3. Ramos-Casals, M., Tzioufas, A.G., Stone, J.H., et alTreatment of primary Sjögren syndrome: A systematic review. JAMA 304(4), 452-460 (2010).